title: Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice.
abstract: Prostate cancer is the most common malignancy among men. Prostate cancer-related deaths are largely attributable to the development of hormone resistance in the tumor. No effective chemotherapy has yet been developed for advanced prostate cancer. It is desirable if a drug can be delivered directly and specifically to prostate cancer cells. Stem cells have selective migration ability toward cancer cells and therapeutic genes can be easily transduced into stem cells. In one form of gene therapy for cancer, the stem cells carry a gene encoding an enzyme that transforms an inert prodrug into a toxic product. Cytosine deaminase (CD) transforms the pro-drug 5-fluorocytosine into highly cytotoxic 5-fluorouracil (5-FU). The migration of the genetically modified stem cells was monitored by molecular magnetic resonance imaging, after labeling the stem cells with fluorescent magnetic nanoparticles (MNPs). Human neural stem cells encoding CD (HB1.F3.CD) were prepared and labeled with MNP. In tumor-bearing C57B mice, systemically transplanted HB1.F3.CD stem cells migrated toward the tumor and in combination with prodrug 5-FC, the volume of tumor implant was significantly reduced. These findings may contribute to development of a new selective chemotherapeutic strategy against prostate cancer.
authors: Medical Research Institute, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
authors: Hong Jun
authors: HJ
authors: Lee
authors: Seung Whan
authors: SW
authors: Doo
authors: Dae Hong
authors: DH
authors: Kim
authors: Young Joo
authors: YJ
authors: Cha
authors: Jae Heon
authors: JH
authors: Kim
authors: Yun Seob
authors: YS
authors: Song
authors: Seung U
authors: SU
authors: Kim
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002465:Cell Movement; D002470:Cell Survival / Q000187:drug effects; D058948:Cell Tracking; D002478:Cells, Cultured; D043525:Cytosine Deaminase / Q000096:biosynthesis*; D005437:Flucytosine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D058953:Neural Stem Cells / Q000201:enzymology / Q000502:physiology / Q000637:transplantation*; D011355:Prodrugs / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D005437:Flucytosine; D043525:Cytosine Deaminase